0LKB.L Stock Analysis
0L
Uncovered
Vanda Pharmaceuticals Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The company is headquartered in Washington, Washington Dc and currently employs 290 full-time employees. The company went IPO on 2006-04-12. Vanda's commercial portfolio is comprised of two products, HETLIOZ for the treatment of jet lag disorder, insomnia, delayed sleep phase disorder (DSPD), sleep disturbances in autism spectrum disorder (ASD) and pediatric Non-24 and Fanapt for the treatment of bipolar I disorder and Parkinsons disease psychosis and a long acting injectable (LAI) formulation for the treatment of schizophrenia. In addition, the Company has a range of drugs in development, including Tradipitant (VLY-686), for the treatment of gastroparesis, motion sickness, atopic dermatitis, and Covid-19 pneumonia; VTR-297 for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications, and VQW-765, for the treatment of performance anxiety and psychiatric disorders.